Somaxon Sleep Aid Silenor Not Effective, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.
You may also be interested in...
Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch
Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.
Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch
Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.
FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo
FDA’s second “complete response” letter for Transcept Pharmaceuticals’s Intermezzo continues the strict scrutiny the agency has given recent candidates for sleep maintenance insomnia indications.